Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Veracyte, Inc. - Common Stock (NQ:VCYT)

24.21 +0.70 (+2.98%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Veracyte, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
VERACYTE INC (NASDAQ:VCYT) – An Undervalued Stock with Strong Fundamentals
VERACYTE INC (NASDAQ:VCYT) is an undervalued biotech stock with strong financial health, solid profitability, and impressive growth prospects, making it a candidate for value investors. 
Via Chartmill
Cathie Wood's Ark Invest Adds Airbnb, AMD, Shopify To Portfolio, Slashes Stake In Circle Internet
Via Benzinga
Cathie Wood's Ark Invest Loads Up On Veracyte, Offloads 3D Systems
Ark Invest made notable trades on Friday, including purchasing shares of Veracyte Inc. and selling shares of 3D Systems Corp. 
Via Benzinga
VERACYTE INC (NASDAQ:VCYT) – A Promising Affordable Growth Stock in Biotechnology
VERACYTE INC (NASDAQ:VCYT) is a biotechnology stock with strong growth, solid profitability, and reasonable valuation, making it an attractive pick for investors seeking affordable growth... 
Via Chartmill
Earnings Scheduled For May 7, 2025
Via Benzinga
A Glimpse Into The Expert Outlook On Veracyte Through 5 Analysts
Via Benzinga
Why VERACYTE INC (NASDAQ:VCYT) qualifies as a high growth stock.
A fundamental and technical analysis of (NASDAQ:VCYT): Is VERACYTE INC (NASDAQ:VCYT) suited for high growth investing? 
Via Chartmill
Demystifying Veracyte: Insights From 7 Analyst Reviews
Via Benzinga
Breaking Down Veracyte: 7 Analysts Share Their Views
Via Benzinga
Veracyte Inc (NASDAQ:VCYT) – An Affordable Growth Stock to Watch
Veracyte Inc (NASDAQ:VCYT) – An Affordable Growth Stock to Watch 
Via Chartmill
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics, Offloads Meta Platforms
ARK Invest made significant trades in NTLA, META, VCYT, SYM, BIDU, and PATH. These moves come amidst changes in stock prices. Read more for full details. 
Via Benzinga
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.
A revolution in oncology could help cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences. 
Via Investor's Business Daily
Despite its growth, VERACYTE INC (NASDAQ:VCYT) remains within the realm of affordability.
Discover VERACYTE INC, an undervalued growth gem. NASDAQ:VCYT is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing... 
Via Chartmill
Exploring NASDAQ:VCYT's high growth characteristics.
Why VERACYTE INC (NASDAQ:VCYT) qualifies as a high growth stock. 
Via Chartmill
Should you consider VERACYTE INC (NASDAQ:VCYT) for high growth investing?
Unlocking the high Growth Potential of VERACYTE INC (NASDAQ:VCYT). 
Via Chartmill
Navigating 9 Analyst Ratings For Veracyte
Via Benzinga
While growth is established for VERACYTE INC (NASDAQ:VCYT), the stock's valuation remains reasonable.
NASDAQ:VCYT is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced. 
Via Chartmill
5 Analysts Assess Veracyte: What You Need To Know
Via Benzinga
Analyst Sees Bottom For Myriad Genetics Stock, Issues Upgrade
Piper Sandler upgrades Myriad Genetics to Overweight, citing stock stabilization and new leadership. The firm raises its price target to $12.50. 
Via Benzinga
VERACYTE INC (NASDAQ:VCYT) stands out as a growth opportunity that won't break the bank.
Discover VERACYTE INC, an undervalued growth gem. NASDAQ:VCYT is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing... 
Via Chartmill
Diagnostic Company Veracyte Weighs Sale For French Subsidiary, Analyst Says 'Walking Away' Is A Long-Term Positive
Veracyte topped Q4 earnings and revenue estimates as testing volume grew. The company is evaluating options for its French unit. 
Via Benzinga
Is NASDAQ:VCYT a Fit for high Growth Investing Strategies?
Should you consider VERACYTE INC (NASDAQ:VCYT) for high growth investing? 
Via Chartmill
Breaking Down Veracyte: 4 Analysts Share Their Views
Via Benzinga
Earnings Scheduled For February 24, 2025
Via Benzinga
Cathie Wood's Ark Invest Trims Palantir Again As Peter Thiel Co-Founded Firm's Stock Tumbles Nearly 15% In 2025
Cathie Wood-led Ark Invest sold 140,518 shares of Palantir and bought shares of Tempus AI Inc. The total value of the trades is about $9.1 million. 
Via Benzinga
Topics Artificial Intelligence
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies. 
Via Benzinga
Topics Artificial Intelligence
Smaller Cap Biotechs Are In Season: How Are We Doing?
SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range. 
Via Talk Markets
Tempus AI Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
A Relative Strength Rating upgrade for Tempus AI shows improving technical performance. 
Via Investor's Business Daily
Topics Artificial Intelligence
Thermo Fisher Scientific Stock Sees RS Rating Jump To 81
Thermo Fisher Scientific stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 77 to 81. 
Via Investor's Business Daily
Lumen Tech & Upstart Are Among Top 7 Mid Cap Gainers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?
Lumen, Upstart, ADMA, Sweetgreen, Veracyte, Clear Secure, and Core Scientific were best performers last week. Did you invest in them? 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.